# GLP-1 Drugs and Athletic Performance: A Growing Competitive Question
Glucagon-like peptide 1 (GLP-1) receptor agonists, including medications like semaglutide and tirzepatide, have become popular for weight loss among athletes and fitness enthusiasts. The question now facing sports regulators: do these drugs create unfair competitive advantages.
The concern centers on how GLP-1 drugs work. They suppress appetite and slow gastric emptying, leading to rapid weight loss. For athletes in weight-class sports like boxing, wrestling, and rowing, this creates a temptation to use the drugs to drop weight quickly before competition. Athletes in sports where lower body weight improves performance, like distance running or gymnastics, face similar incentives.
Sports organizations are beginning to grapple with regulation. The World Anti-Doping Agency (WADA) does not currently ban GLP-1 drugs outright for athletes without diabetes. However, individual sports federations are developing their own policies. Some are implementing stricter guidelines around how much weight athletes can lose in a given timeframe to discourage dangerous rapid weight reduction.
The performance question remains complex. While weight loss itself may help some athletes, the method matters. Rapid weight loss induced by GLP-1 drugs can compromise athletic performance through dehydration, muscle loss, and weakened aerobic capacity. Athletes who lose weight gradually through training and diet typically maintain strength and endurance better than those using pharmacological approaches.
Beyond performance, medical concerns exist. GLP-1 medications carry side effects including nausea, vomiting, and gastrointestinal distress. Athletes without medical necessity for these drugs face unknown long-term effects from off-label use.
The athletic community is watching closely. Some sports organizations are considering adding GLP-1 drugs to banned substance lists